NCT00509665 · OUTCOME

Correlation of Cytotoxicity With Apoptosis in Cancer Cells

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer · Source last updated 2018-07-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: prior to first dose of drug and every 6 weeks for up to 6 months

Analysis population: Data for this endpoint was not collected

Groups in this outcome

Gemcitabine+Doxorubicin

doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle. gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Gemcitabine+Doxorubicin	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

groups

description
doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle. gemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
id
OG000
title
Gemcitabine+Doxorubicin

population Description

Data for this endpoint was not collected

reporting Status

POSTED

time Frame

prior to first dose of drug and every 6 weeks for up to 6 months

title

Correlation of Cytotoxicity With Apoptosis in Cancer Cells

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice